Teva Pharmaceutical Industries Limited Announces U.S. Supreme Court Will Hear Its Appeal on COPAXONE® Patent

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Supreme Court has granted the Company’s COPAXONE® certiorari petition and will hear its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 (the “’808 patent”). The 808 patent expires on September 1, 2015 and claims a process for manufacturing the active ingredient of Teva’s relapsing-remitting multiple sclerosis (RRMS) product, COPAXONE® (glatiramer acetate injection) 20mg/mL. Teva is pleased that the Court has agreed to hear its appeal and Teva remains committed to pursuing all options to protect its intellectual property for COPAXONE®.

Help employers find you! Check out all the jobs and post your resume.

Back to news